Market Overview

Bank of America Reiterates Buy Rating on Optimer


According to Bank of America, Optimer Pharmaceuticals (NASDAQ: OPTR) Buy rating is reiterated.

Bank of America said that Optimer recorded $13.3mn in end market sales for its antibiotic Dificid in 4Q11, a healthy uptick from $6.9mn in 3Q11. “We expect meaningful royalty payments to Cubist in the next 2 years, as we expect the co-marketing alliance to successfully exceed sales targets.”

Optimer Pharmaceuticals closed yesterday at $12.13.

Posted-In: Bank of America Merrill LynchAnalyst Color Reiteration Analyst Ratings


Related Articles (OPTR)

View Comments and Join the Discussion!

Partner Center